Back to dashboard
All PlansAdministrativeMedium impact

08.00.94w, Denosumab (Prolia®, Xgeva®) and related biosimilars, and Romosozumab-aqqg (Evenity®)

Independence Blue Cross·Pharmacy
Effective date
Not stated
We identified it
Jul 2, 2026
Days to comply
—

Summary

Failed to analyze policy change

Action Required

Action needed
Manual review required

Related policy hubs